Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure

Journal of Pharmacology and Experimental Therapeutics

Volumn 301, Issue 3, 2002, Pages 1139-1143

  Kok, R J ^a   Haverdings, R F G ^b   Grijpstra, F ^a   Koiter, J ^a   Moolenaar, F ^c   De Zeeuw, D ^a   Meijer, D K F ^c  

^a Departments of Pharmacokinetics and Drug Delivery   (Netherlands)

^b Clinical Pharmacology   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CAPTOPRIL LYSOZYME; DIPEPTIDYL CARBOXYPEPTIDASE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CAPTOPRIL; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MURAMIDASE; PRODRUGS; RATS; RATS, WISTAR;

EID: 0036264624     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.301.3.1139     Document Type: Article

References (20)

1. Role of local and systemic angiotensin in diabetic renal disease
2. Molecular and biochemical mechanisms of chemically induced nephrotoxicity: A review
3. Comparisons in vitro, ex vivo and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE)
4. A method for accurate measurement of GFR in conscious, spontaneously voiding rats
5. Progression and potential regression of glomerulosclerosis
6. Drug targeting to the kidney with low-molecular-weight proteins
7. Delivery of drugs and antisense oligonucleotides to the proximal tubular cell of the kidney using macromolecular and pro-drug approaches
8. Renal drug targeting: Optimalisation of renal pharmacotherapeutics
9. Potentials and limitations of the low-molecular-weight protein lysozyme as a carrier for renal drug targeting
10. Drug targeting to the kidney: The low-molecular-weight protein approach
11. Sample dilution: A methodological pitfall in measurements of tissue but not serum ACE activity
12. Specific delivery of captopril to the kidneys with the prodrug captopril-lysozyme
13. Bioanalysis of captopril: Two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling
14. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review
15. Tissue angiotensin onverting enzyme inhibition. Relevant to clinical practice?
16. Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension
17. Counteracting progression of renal disease: A look into the future
18. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
19. Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition
20. Tissue renin-angiotensin system: A site of drug action